Clinical characteristics of the patients and recombinant tissue type plasminogen activator (rt-PA) therapy
| Case | Sex | GA (weeks) | Birth weight (g) percentile | Prenatal and postnatal clinical data | Cardiac symptoms | Dose and duration of rt-PA therapy for complete dissolution of the clot | ||||||
| 1 | M | 28 | 640 | PROM; Apgar at 1 min: 2; at 5 min: 5; IPPV for 2 days; streptococcal group B sepsis; death on the 2nd day | No | 0.5 mg/kg in 20 min | ||||||
| <5th | ||||||||||||
| 2 | M | 30 | 1220 | PROM; Apgar at 1 min: 3; at 5 min: 7; IPPV for 6 days; PDA | Yes | 0.5 mg/kg in 30 min | ||||||
| 25th | ||||||||||||
| 3 | F | 33 | 1440 | Caesarean section for maternal hypertension; Apgar at 1 min: 6; at 5 min: 9; IPPV for 3 days | No | 0.4 mg/kg in 30 min | ||||||
| 5th–10th | ||||||||||||
| 4 | M | 26 | 1155 >95th | Abruptio placentae; Apgar at 1 min: 6; at 5 min: 8; right pneumothorax; left atelectasia; HFOV for 4 days; CPAP for 6 days | Yes | 0.4 mg/kg in 30 min followed by 0.1/mg/kg/h for 3 hours | ||||||
GA, Gestational age; PROM, premature rupture of membranes; IPPV, intermittent positive pressure ventilation; HFOV, high frequency oscillatory ventilation; CPAP, continuous positive airway pressure; PDA, patent ductus arteriosus.